EA201691290A1 - BENZODIAZEPINOVA DERIVATIVES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE - Google Patents

BENZODIAZEPINOVA DERIVATIVES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE

Info

Publication number
EA201691290A1
EA201691290A1 EA201691290A EA201691290A EA201691290A1 EA 201691290 A1 EA201691290 A1 EA 201691290A1 EA 201691290 A EA201691290 A EA 201691290A EA 201691290 A EA201691290 A EA 201691290A EA 201691290 A1 EA201691290 A1 EA 201691290A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cognitive impairment
compositions
derivatives
treatment
age
Prior art date
Application number
EA201691290A
Other languages
Russian (ru)
Other versions
EA039381B1 (en
Inventor
Белью Меконнен
Джон А. Батера
Цзяньсин Хуан
Original Assignee
Эйджинбайо, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйджинбайо, Инк. filed Critical Эйджинбайо, Инк.
Priority claimed from PCT/US2014/071644 external-priority patent/WO2015095783A1/en
Publication of EA201691290A1 publication Critical patent/EA201691290A1/en
Publication of EA039381B1 publication Critical patent/EA039381B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Это изобретение относится к бензодиазепиновым производным, композициям, включающим терапевтически эффективные количества этих бензодиазепиновых производных, и способам применения этих производных или композиций в лечении когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС). В частности, оно относится к применению агониста рецептора α5-содержащей ГАМКА (например, положительного аллостерического модулятора рецептора α5-содержащей ГАМКА), как описано здесь, в лечении когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС), у пациента или лица, для которого существует риск развития этого нарушения, включая, без ограничения, пациентов, страдающих, или подвергающихся риску его развития, возрастным когнитивным нарушением, умеренным когнитивным нарушением (MCI), вызывающим нарушение памяти MCI (aMCI), возрастным ухудшением памяти (AAMI), возрастным снижением когнитивных способностей (ARCD), деменцией, болезнью Альцгеймера (AD), продромальной AD, посттравматическим стрессовым расстройством (PTSD), шизофренией, биполярным расстройством, боковым амиотрофическим склерозом (ALS), когнитивным нарушением, связанным с терапией рака, умственной отсталостью, болезнью Паркинсона (PD), нарушениями аутического спектра, синдромом хрупкой X хромосомы, синдромом Ретта, компульсивным поведением и наркотической зависимостью.This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of these benzodiazepine derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with disorders of the central nervous system (CNS). In particular, it relates to the use of an α5-containing GABAA receptor agonist (for example, a positive allosteric modulator of an α5-containing GABAA receptor), as described here, in the treatment of cognitive impairment associated with disorders of the central nervous system (CNS) in a patient or person for which there is a risk of developing this disorder, including, without limitation, patients suffering or at risk of developing it, age-related cognitive impairment, mild cognitive impairment (MCI) causing memory impairment MCI (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (IL) cognitive impairment associated with cancer therapy, mental retardation, Parkinson's disease (PD), autistic spectrum disorders, fragile X chromosome syndrome, Rett syndrome, compulsive behavior, and drug addiction.

EA201691290A 2014-11-05 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment EA039381B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075743P 2014-11-05 2014-11-05
PCT/US2014/071644 WO2015095783A1 (en) 2013-12-20 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (2)

Publication Number Publication Date
EA201691290A1 true EA201691290A1 (en) 2016-11-30
EA039381B1 EA039381B1 (en) 2022-01-20

Family

ID=80685586

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691290A EA039381B1 (en) 2014-11-05 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Country Status (1)

Country Link
EA (1) EA039381B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180475T1 (en) * 1990-09-21 1999-06-15 Rohm & Haas DIHYDROPYRIDAZINONES AND PYRIDAZINONES AS FUNGICIDES
EP0586551A1 (en) * 1991-05-24 1994-03-16 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
EA201390710A1 (en) * 2010-11-15 2013-12-30 Эйджинбайо, Инк. DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE

Also Published As

Publication number Publication date
EA039381B1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2019010577A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
EA201890090A1 (en) DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE
EA201991497A1 (en) Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment
EA201390710A1 (en) DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE
EA202190076A1 (en) BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE DISORDERS
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
AU2019268069A1 (en) Methods and compositions for improving cognitive function
AR085219A1 (en) 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS
EA201391106A1 (en) NEW HETEROCYCLIC DERIVATIVES
EA201390712A1 (en) PYRIDAZIN DERIVATIVES, COMPOSITIONS AND METHODS OF TREATING COGNITIVE DISTURBANCE
EA201491116A1 (en) DERIVATIVES 6-DIFTORMETYL-5,6-DIGIDRO-2H- [1,4] OXAZIN-3-AMINE
EA201290764A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
MA39145B1 (en) Piperazine derivatives having multimode activity against pain
MX2017008083A (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-ami ne compound inhibitors of beta-secretase.
EA201792575A1 (en) PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAMA OF PROLONGED FREEDOM
EA201691831A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS
EA201592277A1 (en) DERIVATIVES 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO [1,5-A] PYRAZINE AS BETA SECRETASE INHIBITORS
MX2022007725A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
IN2013DN11328A (en)
EA201890460A1 (en) COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS
MA47595A (en) TREATMENT METHODS FOR NEURODEGENERATIVE DISORDERS
EA201691788A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS
EA201591021A1 (en) 4-HYDROXY-2-METHIL-5- (PROPAN-2-ILIDEN) CYCLOGEX-3-ENEKARBALDEHYDE IN PREVENTION AND TREATMENT OF COGNITIVE, NEURODEGETERATIVE OR NEURAL DISEASES
EA201890769A1 (en) 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES